U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.

MLA

Ribeiro, Tatiane Bomfim, et al. “U.S. Food and Drug Administration Anticancer Drug Approval Trends from 2016 to 2018 for Lung, Colorectal, Breast, and Prostate Cancer.” International Journal of Technology Assessment in Health Care, vol. 36, no. 1, Jan. 2020, pp. 20–28. EBSCOhost, https://doi.org/10.1017/S0266462319000813.

APA

Ribeiro, T. B., Ribeiro, A., Rodrigues, L. de O., Harada, G., & Nobre, M. R. C. (2020). U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. International Journal of Technology Assessment in Health Care, 36(1), 20–28. https://doi.org/10.1017/S0266462319000813

Chicago

Ribeiro, Tatiane Bomfim, Adalton Ribeiro, Luíza de Oliveira Rodrigues, Guilherme Harada, and Moacyr Roberto Cuce Nobre. 2020. “U.S. Food and Drug Administration Anticancer Drug Approval Trends from 2016 to 2018 for Lung, Colorectal, Breast, and Prostate Cancer.” International Journal of Technology Assessment in Health Care 36 (1): 20–28. doi:10.1017/S0266462319000813.